相关实验视频
Updated: Jun 24, 2025
11:58
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
Published on: August 21, 2021
5.4K
在患有格雷夫斯病的超重和肥胖患者中探索治疗后体重变化:回顾性分析
Maria Leonor Guia Lopes1, Carlos Bello2, José Pedro Cidade3,4
1Endocrinology, Centro Hospitalar Lisboa Ocidental - Hospital Egas Moniz, Lisbon, PRT.
Cureus
|June 3, 2024
概括
格雷夫斯病治疗后体重增加很常见,特别是在超重患者中. 由于与增加的BMI相关的潜在心血管风险,仔细监测至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 心血管健康 心血管健康
背景情况:
- 格雷夫斯病 (GD) 是一种自身免疫性疾病,导致甲状腺功能障碍,往往导致体重减轻.
- 体重增加是GD治疗期间经常发生的情况,有时超过最初的体重减轻.
- 超重和肥胖 (OAO) 患者面临着由体重波动引起的显著代谢和心血管风险.
研究的目的:
- 在治疗期间和治疗后分析格雷夫斯病患者的体重变化.
- 专门调查超重和肥胖 (OAO) GD 患者的体重波动.
- 为了确定与体重增加和治疗后过度体重增加相关的因素.
主要方法:
- 在122名格雷夫病患者的回顾性队列研究中.
- 纳入标准:生物化学甲状腺功能障碍和≥12个月的随访.
- 对纵向体重,人口统计和实验室数据的分析,重点关注BMI≥25kg/m2的个体.
主要成果:
- 在甲状腺功能障碍期间,34.4%的患者出现体重减轻,这与较低的TSH和较长的治疗持续时间有关.
- 大约60%的患者在治疗后体重增加,女性和接受永久治疗的人更为普遍.
- 过度体重增加 (≥26.2%) 与较高的基线BMI和较少的初始体重减轻相关.
结论:
- 治疗后体重增加是格雷夫斯病管理的常见结果.
- 超重和肥胖的GD患者在治疗后体重增加,与较高的初始BMI有关.
- 警的体重管理和早期干预对于OAO GD患者来说至关重要,以减轻心血管风险.
相关概念视频
01:16Insulin: Dosing Regimen and Adverse Effects
166
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
166
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K